Nvidia’s results, Tesla’s European sales, Japan trade - what’s moving markets
Indivior PLC (LON:INDV)’s stock reached a significant milestone, hitting a 52-week high at 17.56 USD. With a market capitalization of $2.2 billion and EBITDA of $309 million, the company has shown strong momentum. According to InvestingPro analysis, analysts have set price targets ranging from $13 to $22. This achievement marks a noteworthy point in the company’s stock performance over the past year. The stock’s upward trajectory is underscored by a 26.11% increase in its value over the last 12 months, with an impressive 41.6% gain over the past six months. This positive momentum reflects investor confidence and the company’s strong market position, as it continues to navigate the complexities of the pharmaceutical industry. The 52-week high signals potential growth opportunities and investor optimism for Indivior’s future performance. InvestingPro subscribers can access 13 additional exclusive tips and comprehensive analysis about Indivior’s financial health and growth prospects.
In other recent news, Indivior PLC has undergone notable leadership changes, as Joe Ciaffoni has been appointed as the new CEO following the departure of Mark Crossley. This change was approved during the company’s Annual General Meeting, alongside amendments to its articles of association, reflecting its transition to Nasdaq as the primary listing. Additionally, Indivior has appointed Patrick Barry as its new Chief Commercial Officer. Barry, who brings over 30 years of pharmaceutical sector experience, will focus on commercial growth strategies, particularly through the company’s SUBLOCADE® product.
In another development, Indivior has welcomed Tony Kingsley to its Board of Directors as an Independent (LON:IOG) Non-Executive Director, effective July 2025. Kingsley’s appointment was supported by affiliates of Oaktree Capital Management under a relationship agreement. On the analyst front, Jefferies has assumed coverage on Indivior with a Buy rating, setting a price target of $20.00. The firm noted that expectations have reset following a challenging period for the company. These recent developments highlight a period of strategic shifts and leadership enhancements for Indivior.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.